^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR495 (MicroRNA 495)

    i
    Other names: MIR495, MicroRNA 495, Hsa-Mir-495, MIRN495, Hsa-Mir-154-P19, Hsa-MiR-495-3p, MIMAT0022924, MIMAT0002817, MI0003135, Mir-495, RF00641
    1m
    Transcriptomics driven identification of hub gene miRNA interactions for biomarker and therapeutic target discovery in gynecological cancers. (PubMed, Front Oncol)
    The identified miRNAs exhibit strong regulatory interactions with these hub genes, while serine/threonine protein kinases emerged as the most significantly associated group. Together, these findings highlight promising biomarker candidates and potential therapeutic targets for gynecological cancers.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • AURKA (Aurora kinase A) • TGFB1 (Transforming Growth Factor Beta 1) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR381 (MicroRNA 381) • MIR495 (MicroRNA 495) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CCNB1 (Cyclin B1) • CDCA8 (Cell Division Cycle Associated 8) • MIR653 (MicroRNA 653)
    2ms
    miRNA as a Prognostic Marker in Small Lung Cell Carcinoma. (PubMed, Genes (Basel))
    In particular, strategies that restore or inhibit miRNA activity using mimics or antagomiRs show promise in improving drug sensitivity and complementing current treatment options. Overall, emerging evidence supports the integration of miRNA profiling into precision oncology for SCLC, with the aim of refining diagnosis, risk assessment and therapeutic decision-making.
    Review • Journal • PARP Biomarker
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • MIR200B (MicroRNA 200b) • TGFB1 (Transforming Growth Factor Beta 1) • MIR100 (MicroRNA 100) • MIR7 (MicroRNA 7) • MIR335 (MicroRNA 335) • MIR494 (MicroRNA 494) • MIR495 (MicroRNA 495) • MIR181B1 (MicroRNA 181b-1) • MIR22 (MicroRNA 22) • MIR30A (MicroRNA 30a) • MIR134 (MicroRNA 134)
    2ms
    Machine learning-based survival prediction in colorectal cancer combining clinical and biological features. (PubMed, Oncotarget)
    Furthermore, our ML model achieved an accuracy of 89.58% to predict patient survival. The clinical and biological features proposed here in conjunction with ML can improve the interpretation of CRC mechanisms and predict patient survival.
    Journal
    |
    MIR495 (MicroRNA 495) • E2F8 (E2F Transcription Factor 8) • WDR77 (WD Repeat Domain 77)
    2ms
    Extrachromosomal circular miRNA-gene amplifications contribute to the renal cancer phenotype. (PubMed, Cell Rep)
    Additionally, we found eccDNA carrying full protein-coding genes that are overexpressed in transcriptional analyses. Our findings suggest that small eccDNAs with miRNA genes are functional and contribute to the tumorigenesis of renal cell carcinoma.
    Journal
    |
    MIR96 (MicroRNA 96) • MIR495 (MicroRNA 495) • MIR196A1 (MicroRNA 196a-1)
    3ms
    The JPX/miR-495-3p/BRD4 axis mediates quercetin-induced toxicity via the X-inactivation center in NSCLC. (PubMed, Curr Res Toxicol)
    Our findings identify quercetin as a natural compound targeting the JPX-miR-495-3p-BRD4 cascade, providing both mechanistic insights and a translational rationale for quercetin-based NSCLC therapy. These findings highlight the therapeutic potential of quercetin in NSCLC and support further exploration of lncRNA-targeted strategies.
    Journal
    |
    BRD4 (Bromodomain Containing 4) • MIR495 (MicroRNA 495) • XIST (X Inactive Specific Transcript)
    3ms
    Intracranial self-stimulation mitigates spatial task deficits, modifies miR-146a and miR-495 serum levels and restores hippocampal NRF2 levels in a rat model of sporadic Alzheimer's disease. (PubMed, Front Aging Neurosci)
    These findings highlight the therapeutic potential of MFB-ICSS as a non-pharmacological intervention in AD. Furthermore, this study confirms NRF2 as a target of miR-495 in the context of AD.
    Preclinical • Journal
    |
    MIR16 (MicroRNA 16) • MIR495 (MicroRNA 495) • MIR191 (MicroRNA 191) • MIR30C
    5ms
    ZWINT down-regulated by miR-495-3p inhibited lung metastasis of breast cancer by blocking p38 MAPK signaling pathway activation. (PubMed, Hum Cell)
    Our findings demonstrate that ZWINT drives breast cancer metastasis and is negatively regulated by miR-495-3p. The newly identified miR-495-3p/ZWINT/p38 MAPK axis may provide a promising therapeutic target for suppressing breast cancer progression.
    Journal
    |
    MIR495 (MicroRNA 495) • ZWINT (ZW10 Interacting Kinetochore Protein)
    9ms
    lncRNA FENDRR Predicts Adverse Prognosis and Regulates the Development of Esophageal Squamous Cell Carcinoma Through Negatively Modulating miR-495-3p. (PubMed, Turk J Gastroenterol)
    Downregulated FENDRR in ESCC predicted the malignant development and adverse prognosis of ESCC patients. FENDRR served as a tumor suppressor of ESCC by modulating miR-495-3p.
    Journal
    |
    MIR495 (MicroRNA 495)
    9ms
    5,7,2',6'- Tetrahydroxyflavone affects the progression of ovarian cancer via hsa-miR-495-3p-ACTB/HSP90AA1 pathway. (PubMed, Discov Oncol)
    TF, an active ingredient of SR, hindered OC progression through the hsa-miR-495-3p-ACTB/HSP90AA1 pathway.
    Journal
    |
    MIR495 (MicroRNA 495) • ANXA5 (Annexin A5) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    10ms
    circ-C20orf11 promotes karyopherin alpha 2 expression through miR-495-3p and affects non-small cell lung cancer development. (PubMed, J Physiol Pharmacol)
    Moreover, the circ-C20orf11 could promote KPNA2 expression by sponging miR-495-3p, and overexpressing KPNA2 impaired the effect of circ-C20orf11 silencing on NSCLC cells. We conclude that circ-C20orf11 accelerates NSCLC via the miR-495-3p/KPNA2 axis.
    Journal
    |
    MIR495 (MicroRNA 495) • KPNA2 (Karyopherin Subunit Alpha 2)
    11ms
    The Practical Landscape of Cytokine-Targeted miRNAs to Enhance NK Cell Function in Cancer Immunotherapy: A Bioinformatic Analysis. (PubMed, Cancer Rep (Hoboken))
    This study highlights the potential of targeting these identified miRNAs as a strategy to enhance NK cell function and improve the efficacy of cancer immunotherapy.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • IL18 (Interleukin 18) • IL15 (Interleukin 15) • MIR340 (MicroRNA 340) • MIR495 (MicroRNA 495) • MIR130A (MicroRNA 130a)
    11ms
    BUB1, miR-495-3p, and E2F1/E2F8 axis is associated with poor prognosis of breast cancer patients and infiltration of Th2 cells in the tumor microenvironment. (PubMed, Cancer Biomark)
    The study revealed a negative correlation between target miRNA miR-495-3p and BUB1 expression in breast cancer tumors, indicating a potential regulatory relationship between these genes. The BUB1 expression was also strongly correlated with the infiltration of CD4+ T helper 2 (Th2) subtypes in the tumors, suggesting a need for further research.
    Journal
    |
    CD4 (CD4 Molecule) • MIR495 (MicroRNA 495) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • E2F1 (E2F transcription factor 1) • E2F8 (E2F Transcription Factor 8)